Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06444399 · ClinicalTrials.gov registry record · Phase 2
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
A Phase 2 study of Pityriasis Rubra Pilaris, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06444399 is a Phase 2 study of Pityriasis Rubra Pilaris that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06444399, a Phase 2 study of Pityriasis Rubra Pilaris, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.
Conditions Studied
Interventions
- DRUG Deucravacitinib
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-29 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06444399
The ClinicalTrials.gov registry entry for NCT06444399 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pityriasis Rubra Pilaris appearing as the primary indexed condition, and to 1 intervention - of which Deucravacitinib is the first listed.
NCT06444399 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06444399 about?
NCT06444399 is a clinical study titled "Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris". The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identific...
What is the current status of trial NCT06444399?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2024-07-29. Estimated completion is 2026-07-01.
What conditions does trial NCT06444399 study?
This clinical trial studies the following conditions: Pityriasis Rubra Pilaris.
What interventions are being tested in trial NCT06444399?
The interventions under investigation include: Deucravacitinib (DRUG).
Who is sponsoring clinical trial NCT06444399?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06444399 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pityriasis Rubra Pilaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.